Antidepressants, Long-Term Use & Heart Risk — What the New Data Is Forcing Us to Reconsider

February 28, 2026

Antidepressants are now used long-term by millions worldwide.

For many individuals with severe depression, they are life-saving. But emerging data suggests we may need to ask more precise questions — especially about long-term exposure and cardiovascular risk.

This is not about fear.

It’s about informed medicine.

The 2025 European Heart Rhythm Association Data

New research presented at the 2025 European Heart Rhythm Association (EHRA) meeting reviewed national death registry data and examined the association between antidepressant duration and sudden cardiac death (SCD).

The pattern observed:

1–5 years of use → ~56% higher risk
6+ years of use → more than double the risk
Adults aged 30–59 showed the steepest relative increase

Importantly, the relationship appeared dose- and time-dependent.

That raises an important question:

Is long-term exposure biologically neutral?

Why Could Antidepressants Affect the Heart?

Several commonly prescribed antidepressants (particularly some SSRIs, SNRIs, and tricyclics) can influence:

Cardiac ion channels
QT interval duration
Electrical conduction pathways

The heart’s rhythm depends on tightly regulated ion movement (sodium, potassium, calcium).

When these channels are altered:

QT prolongation can occur
Arrhythmia risk may increase
Vulnerable individuals may face higher sudden cardiac death risk

Not every antidepressant carries equal risk — but long-term exposure may compound small electrical changes.

The Confounding Variable: Depression Itself

Depression independently correlates with:

Higher inflammation
Metabolic dysfunction
Smoking rates
Reduced physical activity
Sleep disruption
Cardiovascular disease

So separating drug effect from disease effect is complex.

However, what concerned researchers was that risk appeared to increase with longer medication duration, suggesting more than baseline depression alone.

Association is not proof of causation — but patterns matter.

Effectiveness: What Do Large Analyses Show?

Large FDA meta-analyses suggest:

Antidepressants show the strongest benefit in individuals with severe depression
For mild-to-moderate depression, improvement over placebo may be modest
Overall response advantage vs placebo averages around 10–20% in many analyses

This doesn’t mean antidepressants “don’t work.”

It means:

Benefit varies widely
Severity matters
Long-term universal prescribing may not always be justified

The Bigger Issue: Chronic Prescribing

In many cases:

Prescriptions extend for years without reassessment
Lifestyle and metabolic factors remain unaddressed
Root contributors (sleep, inflammation, gut health, trauma, stress load) are under-treated

Medication can stabilize symptoms.

But stabilization is not the same as resolution.

A More Precision-Based Approach

Mental health care may benefit from:

1️⃣ Minimum Effective Dose

Using the lowest dose that achieves clinical stability.

2️⃣ Time-Limited Strategy

Regular reassessment of need rather than indefinite continuation.

3️⃣ Cardiometabolic Monitoring

Tracking:

Resting heart rate
ECG when indicated
Inflammatory markers
Sleep quality
Weight and metabolic status

4️⃣ Root-Biology Support

Addressing:

Sleep regulation
Nutritional deficiencies
Physical activity
Sunlight exposure
Stress response regulation
Psychotherapy

Medication and lifestyle are not opposites.

They should work together.

This Is Not Anti-Medicine

For severe depression, suicidality, or acute crisis:

Antidepressants can be life-saving.

But prescribing them as default, lifelong solutions — without structured reassessment — deserves careful thought.

Both mental and cardiac health deserve protection.

The Core Principle

Mental health care should aim for:

👉 Precision

👉 Minimum necessary exposure

👉 Integrated biological support

Better questions lead to better outcomes.

For the brain.

And for the heart.